Project Code: PN-IV-PCB-RO-MD-2024-0337
Funding Contract No.: 54PCBROMD / 2025
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, driven by profound molecular heterogeneity and lack of targeted therapies.
The BRIGHT-TNBC project addresses this unmet clinical need through a biomarker-guided approach to drug repurposing.
We perform advanced proteomics analyses on human TNBC tissue to identify biomarker signatures and molecular subtypes that guide therapy selection.
TNBC cell lines are characterized based on proteomic similarity to patient tumors, enabling biologically relevant preclinical testing.
We screen approved drugs and combinations, evaluating their molecular and functional effects on TNBC cells to rapidly identify promising therapeutic candidates.
Top candidate therapies are tested in TNBC mouse models, including IVIS imaging and molecular analysis of treatment response.
The project accelerates the discovery of safe, affordable, and clinically translatable therapeutic options through a data-driven, biomarker-guided workflow.
BRIGHT-TNBC strengthens research capacity in Romania and the Republic of Moldova, advancing regional excellence in proteomics, translational oncology and precision medicine.
Cognitive Impact
The BRIGHT-TNBC project contributes to the advancement of scientific knowledge in the field of oncology, particularly in understanding the molecular mechanisms involved in triple-negative breast cancer.
Through the application of high-resolution proteomics, biomarker discovery approaches, and drug repurposing strategies, the project generates new data regarding molecular pathways associated with tumor progression and treatment response.
The results obtained within the project will contribute to the enrichment of the existing scientific knowledge base and will support the development of innovative research directions in precision oncology.
Dissemination of the results through scientific publications, conference presentations, and collaborative research initiatives will facilitate knowledge transfer and integration within the international scientific community.
Socio-Economic Impact
The project addresses a significant public health challenge represented by triple-negative breast cancer, a highly aggressive subtype associated with limited therapeutic options.
By identifying novel biomarkers and evaluating repurposed drugs with potential therapeutic activity, BRIGHT-TNBC may contribute to the development of more effective and cost-efficient treatment strategies.
Drug repurposing approaches have the potential to reduce development time and costs compared to conventional drug discovery, thereby facilitating faster clinical translation.
In addition, the project supports the development of research capacity, strengthens international scientific collaboration between Romania and the Republic of Moldova, and contributes to the training of young researchers in advanced multi-omics technologies and translational biomedical research.